Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) EBIT Margin: 2018-2025

Historic EBIT Margin for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to -96.27%.

  • Arcturus Therapeutics Holdings' EBIT Margin fell 7051.00% to -96.27% in Q3 2025 from the same period last year, while for Sep 2025 it was -80.27%, marking a year-over-year decrease of 3006.00%. This contributed to the annual value of -62.81% for FY2024, which is 1593.00% down from last year.
  • According to the latest figures from Q3 2025, Arcturus Therapeutics Holdings' EBIT Margin is -96.27%, which was down 134.56% from -41.04% recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' EBIT Margin's 5-year high stood at 75.77% during Q4 2022, with a 5-year trough of -2,711.14% in Q1 2021.
  • Moreover, its 3-year median value for EBIT Margin was -57.27% (2025), whereas its average is -99.95%.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' EBIT Margin slumped by 235,355bps in 2021, and later soared by 260,313bps in 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' EBIT Margin (Quarterly) stood at -649.72% in 2021, then skyrocketed by 72,549bps to 75.77% in 2022, then crashed by 13,499bps to -59.22% in 2023, then plummeted by 8,746bps to -146.68% in 2024, then tumbled by 7,051bps to -96.27% in 2025.
  • Its EBIT Margin stands at -96.27% for Q3 2025, versus -41.04% for Q2 2025 and -57.27% for Q1 2025.